首页 > 最新文献

Kidney Research and Clinical Practice最新文献

英文 中文
Management of high-flow arteriovenous access.
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.23876/j.krcp.23.196
Hoon Suk Park, Seok Joon Shin

An arteriovenous fistula or graft is essential for hemodialysis (HD). It involves connecting a high-resistance artery to a low-resistance vein, which increases cardiac output (CO). In the early days of HD, patients with end-stage kidney disease (ESKD) were typically younger, and their HD access was located in the distal forearm. However, in the modern era, ESKD patients are often the elderly, with many being the very elderly (over 80 years old). These elderly patients often have poor vessel quality, making distal forearm access unsuitable. As a result, upper arm access, which is more prone to high-flow access, is commonly used. The cardiac status of these modern elderly ESKD patients is vulnerable to high-flow access. High-flow HD access can lead to high-output cardiac failure in ESKD patients. Initial evaluation for high-flow access involves measuring the flow volume using Doppler ultrasound. If the HD access flow volume exceeds 2,000 mL/min, further assessments, including CO and cardiopulmonary recirculation ratio caused by the HD access, should be strongly considered. Treatment for high-flow access involves reducing the flow. There are several surgical and endovascular methods for flow reduction, such as aneurysmorrhaphy, short segment small-diameter graft interposition at the inflow area of the HD access, and banding. Patients with high-flow access are generally asymptomatic. Therefore, nephrologists as primary care physicians for HD patients should provide detailed explanations to patients with high-flow access and high-output cardiac failure and ensure that they understand the prognosis of these conditions. Nephrologists need increased attention to high-flow HD access.

{"title":"Management of high-flow arteriovenous access.","authors":"Hoon Suk Park, Seok Joon Shin","doi":"10.23876/j.krcp.23.196","DOIUrl":"10.23876/j.krcp.23.196","url":null,"abstract":"<p><p>An arteriovenous fistula or graft is essential for hemodialysis (HD). It involves connecting a high-resistance artery to a low-resistance vein, which increases cardiac output (CO). In the early days of HD, patients with end-stage kidney disease (ESKD) were typically younger, and their HD access was located in the distal forearm. However, in the modern era, ESKD patients are often the elderly, with many being the very elderly (over 80 years old). These elderly patients often have poor vessel quality, making distal forearm access unsuitable. As a result, upper arm access, which is more prone to high-flow access, is commonly used. The cardiac status of these modern elderly ESKD patients is vulnerable to high-flow access. High-flow HD access can lead to high-output cardiac failure in ESKD patients. Initial evaluation for high-flow access involves measuring the flow volume using Doppler ultrasound. If the HD access flow volume exceeds 2,000 mL/min, further assessments, including CO and cardiopulmonary recirculation ratio caused by the HD access, should be strongly considered. Treatment for high-flow access involves reducing the flow. There are several surgical and endovascular methods for flow reduction, such as aneurysmorrhaphy, short segment small-diameter graft interposition at the inflow area of the HD access, and banding. Patients with high-flow access are generally asymptomatic. Therefore, nephrologists as primary care physicians for HD patients should provide detailed explanations to patients with high-flow access and high-output cardiac failure and ensure that they understand the prognosis of these conditions. Nephrologists need increased attention to high-flow HD access.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":"44 1","pages":"58-68"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bowman capsule rupture in children with myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis predicts poor renal survival. 患有髓过氧化物酶-抗中性粒细胞胞浆抗体相关肾小球肾炎的儿童Bowman囊破裂预示着肾存活率低。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2023-11-01 DOI: 10.23876/j.krcp.23.051
Pei Zhang, Li-Li Jia, Meng-Zhen Fu, Kai-Li Shi, Chun-Lin Gao, Zheng-Kun Xia

Background: Recent developments indicated that Bowman capsule rupture (BCR) is observed in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN). We aimed to explore the relationship between BCR and clinical manifestations, pathological changes, and prognosis in children with myeloperoxidase (MPO)-AAGN.

Methods: A total of 56 children with MPO-AAGN were divided into BCR (+) and BCR (-) groups according to the status of Bowman's capsule.

Results: After retrospective analysis of the data, 24 children (42.9%) were found to have BCR. The results showed that BCR positively correlated with intrarenal immune cell infiltrates, obsolescence and crescents in glomeruli, tubulointerstitial inflammation, tubulitis, and tubular atrophy negatively correlated with normal glomeruli and immunoglobulin G deposition in the kidney. The clinical features and kidney pathological changes were more severe in the BCR (+) group than BCR (-) group, and the renal survival rate was significantly poorer in the BCR (+) group than BCR (-) group (χ2 = 5.45, p = 0.02). Moreover, estimated glomerular filtration rate (≤15 mL/ min/1.73 m2), BCR and ANCA renal risk score (ARRS) were independent risk factors for the development of end-stage kidney disease (ESKD) in children with MPO-AAGN. After combining BCR with the Berden classification and ARRS, our data suggested that the Berden classification + BCR and ARRS + BCR showed better predictive values for ESKD than those of the Berden classification and ARRS, respectively.

Conclusion: BCR is an important pathological lesion that correlates with severe clinical manifestations, pathological changes, and poor prognosis in children with MPO-AAGN.

背景:最近的研究表明,在抗中性粒细胞胞浆抗体(ANCA)相关肾小球肾炎(AAGN)中观察到鲍曼囊破裂(BCR)。我们旨在探讨髓过氧化物酶(MPO)-AAGN患儿的BCR与临床表现、病理变化和预后之间的关系。比较了MPO-AAGN的临床和组织学特征以及肾脏预后,并评估了BCR对终末期肾脏疾病(ESKD)的预测价值。结果:对数据进行回顾性分析后,发现24名儿童(42.9%)患有BCR。结果显示,BCR与肾内免疫细胞浸润、肾小球陈旧和新月形细胞呈正相关,肾小管间质炎症、肾小管炎和肾小管萎缩与正常肾小球和肾中免疫球蛋白G沉积呈负相关。BCR(+)组的临床特征和肾脏病理变化比BCR(-)组更严重,肾存活率明显低于BCR(-1)组(χ2=5.45,p=0.02),BCR和ANCA肾脏风险评分(ARRS)是MPO-AAGN患儿发生ESKD的独立危险因素。在将BCR与Berden分类法和ARRS相结合后,我们的数据表明,Berden分类+BCR和ARRS+BCR分别比Berden分类和ARRS对ESKD显示出更好的预测值。结论:BCR是MPO-AAGN患儿的一种重要病理病变,与严重的临床表现、病理变化和不良预后有关。
{"title":"Bowman capsule rupture in children with myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis predicts poor renal survival.","authors":"Pei Zhang, Li-Li Jia, Meng-Zhen Fu, Kai-Li Shi, Chun-Lin Gao, Zheng-Kun Xia","doi":"10.23876/j.krcp.23.051","DOIUrl":"10.23876/j.krcp.23.051","url":null,"abstract":"<p><strong>Background: </strong>Recent developments indicated that Bowman capsule rupture (BCR) is observed in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (AAGN). We aimed to explore the relationship between BCR and clinical manifestations, pathological changes, and prognosis in children with myeloperoxidase (MPO)-AAGN.</p><p><strong>Methods: </strong>A total of 56 children with MPO-AAGN were divided into BCR (+) and BCR (-) groups according to the status of Bowman's capsule.</p><p><strong>Results: </strong>After retrospective analysis of the data, 24 children (42.9%) were found to have BCR. The results showed that BCR positively correlated with intrarenal immune cell infiltrates, obsolescence and crescents in glomeruli, tubulointerstitial inflammation, tubulitis, and tubular atrophy negatively correlated with normal glomeruli and immunoglobulin G deposition in the kidney. The clinical features and kidney pathological changes were more severe in the BCR (+) group than BCR (-) group, and the renal survival rate was significantly poorer in the BCR (+) group than BCR (-) group (χ2 = 5.45, p = 0.02). Moreover, estimated glomerular filtration rate (≤15 mL/ min/1.73 m2), BCR and ANCA renal risk score (ARRS) were independent risk factors for the development of end-stage kidney disease (ESKD) in children with MPO-AAGN. After combining BCR with the Berden classification and ARRS, our data suggested that the Berden classification + BCR and ARRS + BCR showed better predictive values for ESKD than those of the Berden classification and ARRS, respectively.</p><p><strong>Conclusion: </strong>BCR is an important pathological lesion that correlates with severe clinical manifestations, pathological changes, and poor prognosis in children with MPO-AAGN.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"111-122"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71424669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Loss of Cutibacterium is responsible for chronic kidney disease-associated pruritus in patients on dialysis. Cutibacterium的缺失是透析患者慢性肾脏疾病相关瘙痒的原因。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2023-09-06 DOI: 10.23876/j.krcp.23.057
Jeong Geon Lee, Hoonhee Seo, Seung Seob Son, Hee Seul Jeong, Kyung Mi Lee, Nam-Jun Cho, Samel Park, Hyo-Wook Gil, Hyun-A Park, Sukyung Kim, Eun Young Lee

Background: Chronic kidney disease (CKD)-associated pruritus is a severe distressing condition that frequently occurs in patients undergoing dialysis. In this study, the profile of the skin microbiome was analyzed to understand the underlying etiology and potential treatments.

Methods: Seventy-six end-stage kidney disease (ESKD) patients (hemodialysis, 40; peritoneal dialysis, 36) and 15 healthy controls were enrolled and swabbed at three sites: back, antecubital fossa, and shin. The pruritus severity of the enrolled subjects was validated by the Worst Itch Numeric Rating Scale (WI-NRS), 5-D itch scale, and Uremic Pruritus in Dialysis Patients (UP-Dial). The 16S genebased metagenomics method was applied to skin microbiome analysis.

Results: In the comparison of bacterial communities of ESKD patients and the control group, there was a significant difference on back. Specifically, the average composition ratio of the Cutibacterium in the back samples was significantly lower in ESKD patients than in healthy controls (p < 0.01). In further analysis of ESKD patients, Cutibacterium was significantly lower in the high pruritus group than in the low pruritus group (p < 0.05), even though other clinical parameters such as age, calcium-phosphorus product, and intact parathyroid hormone showed no significance difference between the groups.

Conclusion: In ESKD patients, the skin microbiome of the back was significantly altered, and the severity of itching was related to the reduction of Cutibacterium. This research reveals the relationship between skin microbiota and CKD-associated pruritus in multiple skin sites for the first time. The results of this study suggest a potential data basis for the diagnosis and treatment of CKD-associated pruritus.

背景:慢性肾脏病(CKD)相关瘙痒症是一种严重的痛苦状况,经常发生在接受透析的患者中。在这项研究中,分析了皮肤微生物组的概况,以了解潜在的病因和潜在的治疗方法。方法:76名终末期肾病(ESKD)患者(血液透析,40名;腹膜透析,36名)和15名健康对照者被纳入研究,并在背部、前窝和胫骨三个部位进行拭子检查。入选受试者的瘙痒严重程度通过最差瘙痒数值评定量表(WI-NRS)、5-D瘙痒量表和透析患者的尿毒症瘙痒(UP-Dial)进行验证。将基于16S基因的宏基因组学方法应用于皮肤微生物组分析。结果:ESKD患者背部细菌群落与对照组比较,差异有统计学意义。具体而言,ESKD患者背部样本中Cutibacterium的平均组成比显著低于健康对照组(p<0.01)。在对ESKD患者的进一步分析中,尽管其他临床参数如年龄、钙磷产品、,完整的甲状旁腺激素组间无显著性差异。结论:ESKD患者背部皮肤微生物组发生明显改变,瘙痒的严重程度与皮肤细菌减少有关。这项研究首次揭示了多个皮肤部位的皮肤微生物群与CKD相关瘙痒之间的关系。这项研究的结果为CKD相关瘙痒的诊断和治疗提供了潜在的数据基础。
{"title":"Loss of Cutibacterium is responsible for chronic kidney disease-associated pruritus in patients on dialysis.","authors":"Jeong Geon Lee, Hoonhee Seo, Seung Seob Son, Hee Seul Jeong, Kyung Mi Lee, Nam-Jun Cho, Samel Park, Hyo-Wook Gil, Hyun-A Park, Sukyung Kim, Eun Young Lee","doi":"10.23876/j.krcp.23.057","DOIUrl":"10.23876/j.krcp.23.057","url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD)-associated pruritus is a severe distressing condition that frequently occurs in patients undergoing dialysis. In this study, the profile of the skin microbiome was analyzed to understand the underlying etiology and potential treatments.</p><p><strong>Methods: </strong>Seventy-six end-stage kidney disease (ESKD) patients (hemodialysis, 40; peritoneal dialysis, 36) and 15 healthy controls were enrolled and swabbed at three sites: back, antecubital fossa, and shin. The pruritus severity of the enrolled subjects was validated by the Worst Itch Numeric Rating Scale (WI-NRS), 5-D itch scale, and Uremic Pruritus in Dialysis Patients (UP-Dial). The 16S genebased metagenomics method was applied to skin microbiome analysis.</p><p><strong>Results: </strong>In the comparison of bacterial communities of ESKD patients and the control group, there was a significant difference on back. Specifically, the average composition ratio of the Cutibacterium in the back samples was significantly lower in ESKD patients than in healthy controls (p < 0.01). In further analysis of ESKD patients, Cutibacterium was significantly lower in the high pruritus group than in the low pruritus group (p < 0.05), even though other clinical parameters such as age, calcium-phosphorus product, and intact parathyroid hormone showed no significance difference between the groups.</p><p><strong>Conclusion: </strong>In ESKD patients, the skin microbiome of the back was significantly altered, and the severity of itching was related to the reduction of Cutibacterium. This research reveals the relationship between skin microbiota and CKD-associated pruritus in multiple skin sites for the first time. The results of this study suggest a potential data basis for the diagnosis and treatment of CKD-associated pruritus.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"176-188"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zebra bodies in lupus nephritis without Fabry disease or hydroxychloroquine therapy.
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-17 DOI: 10.23876/j.krcp.24.283
Yaning Wang, Rongdan Cai, Yunqi Liu, Ning Yu, Mingfeng Zhao
{"title":"Zebra bodies in lupus nephritis without Fabry disease or hydroxychloroquine therapy.","authors":"Yaning Wang, Rongdan Cai, Yunqi Liu, Ning Yu, Mingfeng Zhao","doi":"10.23876/j.krcp.24.283","DOIUrl":"10.23876/j.krcp.24.283","url":null,"abstract":"","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"210-212"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical guidelines for the diagnosis, evaluation, and management of hypertension for Korean children and adolescents: the Korean Working Group of Pediatric Hypertension.
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-31 DOI: 10.23876/j.krcp.24.096
Se Jin Park, Hyo Soon An, Sung Hye Kim, Seong Heon Kim, Hee Yeon Cho, Jae Hyun Kim, Anna Cho, Ji Hee Kwak, Jae Il Shin, Keum Hwa Lee, Jin-Hee Oh, Jung Won Lee, Hae Soon Kim, Hye-Jung Shin, Mi Young Han, Myung Chul Hyun, Tae Sun Ha, Young Hwan Song

Pediatric hypertension (HTN) is a significant, growing health concern worldwide and also in Korea. Diagnosis, evaluation, and treatment of HTN in Korean children and adolescents are uncertain due to limitations in using the current international guidelines, since the recommendations by the American Academy of Pediatrics (AAP) and European Society of Hypertension (ESH) guidelines differ. Furthermore, these are guidelines for Western youth, who are racially and ethnically different from Koreans. In addition, reference blood pressure values for all pediatric age groups, which are essential for the diagnosis of HTN according to these two guidelines, are absent in Korea. Therefore, HTN guidelines for Korean children and adolescents should be established. The Korean Working Group of Pediatric Hypertension established clinical guidelines for the diagnosis, evaluation, and management of HTN in Korean children and adolescents. These guidelines were based on reported clinical evidence, expert recommendations, and AAP and ESH guidelines. The characteristics of Korean youth and the Korean medical and insurance system were considered during the establishment of the guidelines. By providing recommendations suitable for Korean youth, these guidelines will help in the prevention and management of childhood HTN, thus relieving the burden of cardiovascular disease in adulthood in Korea.

{"title":"Clinical guidelines for the diagnosis, evaluation, and management of hypertension for Korean children and adolescents: the Korean Working Group of Pediatric Hypertension.","authors":"Se Jin Park, Hyo Soon An, Sung Hye Kim, Seong Heon Kim, Hee Yeon Cho, Jae Hyun Kim, Anna Cho, Ji Hee Kwak, Jae Il Shin, Keum Hwa Lee, Jin-Hee Oh, Jung Won Lee, Hae Soon Kim, Hye-Jung Shin, Mi Young Han, Myung Chul Hyun, Tae Sun Ha, Young Hwan Song","doi":"10.23876/j.krcp.24.096","DOIUrl":"10.23876/j.krcp.24.096","url":null,"abstract":"<p><p>Pediatric hypertension (HTN) is a significant, growing health concern worldwide and also in Korea. Diagnosis, evaluation, and treatment of HTN in Korean children and adolescents are uncertain due to limitations in using the current international guidelines, since the recommendations by the American Academy of Pediatrics (AAP) and European Society of Hypertension (ESH) guidelines differ. Furthermore, these are guidelines for Western youth, who are racially and ethnically different from Koreans. In addition, reference blood pressure values for all pediatric age groups, which are essential for the diagnosis of HTN according to these two guidelines, are absent in Korea. Therefore, HTN guidelines for Korean children and adolescents should be established. The Korean Working Group of Pediatric Hypertension established clinical guidelines for the diagnosis, evaluation, and management of HTN in Korean children and adolescents. These guidelines were based on reported clinical evidence, expert recommendations, and AAP and ESH guidelines. The characteristics of Korean youth and the Korean medical and insurance system were considered during the establishment of the guidelines. By providing recommendations suitable for Korean youth, these guidelines will help in the prevention and management of childhood HTN, thus relieving the burden of cardiovascular disease in adulthood in Korea.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":"44 1","pages":"20-48"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11864819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical consequence of hypophosphatemia during antiviral therapy for chronic hepatitis B.
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2025-01-17 DOI: 10.23876/j.krcp.22.197
Mee Yeon Park, Hojin Jeon, Kyungho Park, Junseok Jeon, Minsu Park, Sang Ah Chi, Kyunga Kim, Dong Hyun Sinn, Jung Eun Lee, Geum-Youn Gwak, Wooseong Huh, Yoon-Goo Kim, Hye Ryoun Jang

Background: Antiviral therapy is an essential treatment for chronic hepatitis B (CHB) infection. Although hypophosphatemia is an important adverse effect of antiviral agents, its clinical significance remains unclear. We investigated the incidence and clinical consequences of hypophosphatemia in a large cohort of CHB patients.

Methods: This retrospective cohort study included CHB patients who started antiviral therapy between 2005 and 2015 and continued it for at least 1 year. Patients with decompensated liver cirrhosis, diabetes mellitus, hypertension, concomitant diuretic administration, and end-stage renal disease were excluded. The primary outcome was a change in renal function. Secondary outcomes included the incidence of infection and changes in serum potassium, uric acid, and total carbon dioxide (tCO2).

Results: Among the 4,335 patients, hypophosphatemia developed in 75 (1.7%). During the median 2-year follow-up period, patients with hypophosphatemia showed a lower estimated glomerular filtration rate than those in the control group. The incidence of infection and changes in serum potassium, uric acid, and tCO2 were similar between groups.

Conclusion: Hypophosphatemia was associated with a renal function decline in patients with CHB receiving antiviral therapy.

{"title":"Clinical consequence of hypophosphatemia during antiviral therapy for chronic hepatitis B.","authors":"Mee Yeon Park, Hojin Jeon, Kyungho Park, Junseok Jeon, Minsu Park, Sang Ah Chi, Kyunga Kim, Dong Hyun Sinn, Jung Eun Lee, Geum-Youn Gwak, Wooseong Huh, Yoon-Goo Kim, Hye Ryoun Jang","doi":"10.23876/j.krcp.22.197","DOIUrl":"10.23876/j.krcp.22.197","url":null,"abstract":"<p><strong>Background: </strong>Antiviral therapy is an essential treatment for chronic hepatitis B (CHB) infection. Although hypophosphatemia is an important adverse effect of antiviral agents, its clinical significance remains unclear. We investigated the incidence and clinical consequences of hypophosphatemia in a large cohort of CHB patients.</p><p><strong>Methods: </strong>This retrospective cohort study included CHB patients who started antiviral therapy between 2005 and 2015 and continued it for at least 1 year. Patients with decompensated liver cirrhosis, diabetes mellitus, hypertension, concomitant diuretic administration, and end-stage renal disease were excluded. The primary outcome was a change in renal function. Secondary outcomes included the incidence of infection and changes in serum potassium, uric acid, and total carbon dioxide (tCO2).</p><p><strong>Results: </strong>Among the 4,335 patients, hypophosphatemia developed in 75 (1.7%). During the median 2-year follow-up period, patients with hypophosphatemia showed a lower estimated glomerular filtration rate than those in the control group. The incidence of infection and changes in serum potassium, uric acid, and tCO2 were similar between groups.</p><p><strong>Conclusion: </strong>Hypophosphatemia was associated with a renal function decline in patients with CHB receiving antiviral therapy.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"123-131"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11877809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients. 通过治疗药物监测,确认在新肾移植受者中减少固定剂量的霉酚酸酯的安全性。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-10-24 DOI: 10.23876/j.krcp.23.274
Hee-Yeon Jung, Yu Jin Seo, Deokbi Hwang, Woo-Sung Yun, Hyung-Kee Kim, Seung Huh, Eun Sang Yoo, Jeong-Hoon Lim, Ji-Young Choi, Sun-Hee Park, Yong-Lim Kim, Dong Il Won, Jang-Hee Cho, Chan-Duck Kim

Background: Mycophenolate mofetil (MMF) is usually prescribed with a reduced fixed dose in Asian kidney transplant recipients (KTRs). However, the clinical efficacy and safety of the fixed dose have not yet been investigated via therapeutic drug monitoring. We evaluated whether reduced fixed-dose MMF is an optimal dosing strategy to achieve the therapeutic target of mycophenolic acid (MPA) exposure in Korean KTRs.

Methods: This open-label, prospective study enrolled 50 de novo KTRs prescribed with tacrolimus, corticosteroid, and fixed-dose MMF (1.0-1.5 g/day). The trough level (C0) and area under the curve (AUC0-12 hr) of MPA were measured at 1 and 24 weeks after kidney transplantation (KT). The relationship of body weight (BW)-adjusted MMF dose with MPA C0 and MPA AUC0-12 hr was assessed using linear regression analysis.

Results: The initial fixed dose of MMF of 1.44 ± 0.16 g/day was adjusted in 24 patients (48.0%) and then reduced to a mean dose of 1.19 ± 0.31 g/day at 24 weeks after KT. Most patients (≥84.0%) attained the minimum required MPA C0 of 1.0 μg/mL and MPA AUC0-12 hr of 30 μg × hr/mL at 1 and 24 weeks. The BW-adjusted MMF dose demonstrated significant positive correlations with MPA C0 and MPA AUC0- 12 hr at 1 and 24 weeks after KT. Moreover, 14 patients (28.0%) reported MPA-related adverse events that were predictable based on MPA AUC0-12 hr (cutoff level, 46.4 μg × hr/mL).

Conclusion: The current reduced fixed-dose MMF strategy can help achieve the therapeutic target of MPA exposure in tacrolimus- treated Korean KTRs during the early posttransplant period.

背景:亚洲肾移植受者(KTR)通常在处方中减少霉酚酸酯(MMF)的固定剂量。然而,尚未通过治疗药物监测对固定剂量的临床疗效和安全性进行研究。我们评估了在韩国肾移植受者中,减少固定剂量的MMF是否是实现霉酚酸(MPA)暴露治疗目标的最佳给药策略:这项开放标签、前瞻性研究共纳入了50名使用他克莫司、皮质类固醇和固定剂量MMF(1.0-1.5克/天)的新KTR。在肾移植(KT)后1周和24周测量了MPA的谷值(C0)和曲线下面积(AUC0-12 hr)。采用线性回归分析评估了体重(BW)调整后的MMF剂量与MPA C0和MPA AUC0-12 hr的关系:24名患者(48.0%)调整了MMF的初始固定剂量(1.44±0.16克/天),然后在KT 24周后将平均剂量降至1.19±0.31克/天。大多数患者(≥84.0%)在 1 周和 24 周达到了最低要求的 MPA C0 1.0 μg/mL 和 MPA AUC0-12 hr 30 μg × hr/mL。体重调整后的 MMF 剂量与 KT 后 1 周和 24 周的 MPA C0 和 MPA AUC0-12 hr 呈显著正相关。此外,14 名患者(28.0%)报告了与 MPA 相关的不良事件,这些不良事件可根据 MPA AUC0-12 hr(临界值,46.4 μg × hr/mL)预测:结论:目前的减量固定剂量 MMF 策略有助于实现他克莫司治疗的韩国 KTR 移植后早期的 MPA 暴露治疗目标。
{"title":"Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients.","authors":"Hee-Yeon Jung, Yu Jin Seo, Deokbi Hwang, Woo-Sung Yun, Hyung-Kee Kim, Seung Huh, Eun Sang Yoo, Jeong-Hoon Lim, Ji-Young Choi, Sun-Hee Park, Yong-Lim Kim, Dong Il Won, Jang-Hee Cho, Chan-Duck Kim","doi":"10.23876/j.krcp.23.274","DOIUrl":"10.23876/j.krcp.23.274","url":null,"abstract":"<p><strong>Background: </strong>Mycophenolate mofetil (MMF) is usually prescribed with a reduced fixed dose in Asian kidney transplant recipients (KTRs). However, the clinical efficacy and safety of the fixed dose have not yet been investigated via therapeutic drug monitoring. We evaluated whether reduced fixed-dose MMF is an optimal dosing strategy to achieve the therapeutic target of mycophenolic acid (MPA) exposure in Korean KTRs.</p><p><strong>Methods: </strong>This open-label, prospective study enrolled 50 de novo KTRs prescribed with tacrolimus, corticosteroid, and fixed-dose MMF (1.0-1.5 g/day). The trough level (C0) and area under the curve (AUC0-12 hr) of MPA were measured at 1 and 24 weeks after kidney transplantation (KT). The relationship of body weight (BW)-adjusted MMF dose with MPA C0 and MPA AUC0-12 hr was assessed using linear regression analysis.</p><p><strong>Results: </strong>The initial fixed dose of MMF of 1.44 ± 0.16 g/day was adjusted in 24 patients (48.0%) and then reduced to a mean dose of 1.19 ± 0.31 g/day at 24 weeks after KT. Most patients (≥84.0%) attained the minimum required MPA C0 of 1.0 μg/mL and MPA AUC0-12 hr of 30 μg × hr/mL at 1 and 24 weeks. The BW-adjusted MMF dose demonstrated significant positive correlations with MPA C0 and MPA AUC0- 12 hr at 1 and 24 weeks after KT. Moreover, 14 patients (28.0%) reported MPA-related adverse events that were predictable based on MPA AUC0-12 hr (cutoff level, 46.4 μg × hr/mL).</p><p><strong>Conclusion: </strong>The current reduced fixed-dose MMF strategy can help achieve the therapeutic target of MPA exposure in tacrolimus- treated Korean KTRs during the early posttransplant period.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"200-209"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nephrology consultation improves the clinical outcomes of patients with acute kidney injury. 肾病咨询可改善急性肾损伤患者的临床结果。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2023-09-08 DOI: 10.23876/j.krcp.23.039
Harin Rhee, Meeyoung Park, Il Young Kim

Background: Acute kidney injury (AKI) is prevalent in critically ill patients and is associated with an increased risk of in-hospital mortality. Nephrology consultation may be protective, but this has rarely been evaluated in South Korea.

Methods: This multicenter retrospective study was based on the electronic medical records (EMRs) of two third-affiliated hospitals. We extracted the records of patients admitted to intensive care units (ICUs) between 2011 and 2020, and retrospectively detected AKI using the modified serum creatinine criteria of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The AKI diagnosis date was defined as the first day of a significant change in serum creatinine level (≥0.3 mg/dL) within 48 hours. Nephrology consultation status was retrieved from the EMRs.

Results: In total, 2,461 AKI patients were included; the median age was 65 years (interquartile range [IQR], 56-75 years), 1,459 (59.3%) were male, and 1,065 (43.3%) were of AKI stage 3. During a median of 5 days (IQR, 3-11 days) of ICU admission, nephrology consultations were provided to 512 patients (20.8%). Patients who received such consultations were older, had more comorbidities, and more commonly required dialysis. In a multivariable model, nephrology consultation reduced the risk of in-hospital mortality by 30% (hazard ratio, 0.71; 95% confidence interval, 0.57-0.88). Other factors significant for in-hospital mortality were older age, a higher sequential organ failure assessment (SOFA) score, sepsis, diabetes, hypertension, heart disease, and cancer.

Conclusion: For AKI patients in ICUs, nephrology consultation reduced the risk of in-hospital mortality, particularly among those with multiple comorbidities. Therefore, nephrology consultation should not be omitted during ICU care.

背景:急性肾损伤(AKI)在危重患者中普遍存在,并与住院死亡风险增加有关。肾病咨询可能具有保护作用,但在韩国很少对此进行评估。方法:这项多中心回顾性研究基于两家第三附属医院的电子病历(EMR)。我们提取了2011年至2020年间入住重症监护室(ICU)的患者的记录,并使用肾脏疾病:改善全球结果(KDIGO)指南的改良血清肌酐标准对AKI进行了回顾性检测。AKI诊断日期定义为48小时内血清肌酐水平发生显著变化(≥0.3 mg/dL)的第一天。结果:共纳入2461例AKI患者;中位年龄为65岁(四分位间距[IQR],56-75岁),1459人(59.3%)为男性,1065人(43.3%)为AKI 3期。在ICU入院的平均5天(IQR,3-11天)内,共为512名患者(20.8%)提供了肾脏病咨询。接受此类咨询的患者年龄较大,合并症较多,更常见的是需要透析。在一个多变量模型中,肾病咨询将住院死亡率降低了30%(危险比为0.71;95%置信区间为0.57-0.88)。其他对住院死亡率有重要意义的因素包括年龄较大、连续器官衰竭评估(SOFA)评分较高、败血症、糖尿病、高血压、心脏病和癌症。结论:对于重症监护室的AKI患者,肾脏科会诊降低了住院死亡率的风险,尤其是在患有多种合并症的患者中。因此,在ICU护理期间不应省略肾脏病咨询。
{"title":"Nephrology consultation improves the clinical outcomes of patients with acute kidney injury.","authors":"Harin Rhee, Meeyoung Park, Il Young Kim","doi":"10.23876/j.krcp.23.039","DOIUrl":"10.23876/j.krcp.23.039","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is prevalent in critically ill patients and is associated with an increased risk of in-hospital mortality. Nephrology consultation may be protective, but this has rarely been evaluated in South Korea.</p><p><strong>Methods: </strong>This multicenter retrospective study was based on the electronic medical records (EMRs) of two third-affiliated hospitals. We extracted the records of patients admitted to intensive care units (ICUs) between 2011 and 2020, and retrospectively detected AKI using the modified serum creatinine criteria of the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The AKI diagnosis date was defined as the first day of a significant change in serum creatinine level (≥0.3 mg/dL) within 48 hours. Nephrology consultation status was retrieved from the EMRs.</p><p><strong>Results: </strong>In total, 2,461 AKI patients were included; the median age was 65 years (interquartile range [IQR], 56-75 years), 1,459 (59.3%) were male, and 1,065 (43.3%) were of AKI stage 3. During a median of 5 days (IQR, 3-11 days) of ICU admission, nephrology consultations were provided to 512 patients (20.8%). Patients who received such consultations were older, had more comorbidities, and more commonly required dialysis. In a multivariable model, nephrology consultation reduced the risk of in-hospital mortality by 30% (hazard ratio, 0.71; 95% confidence interval, 0.57-0.88). Other factors significant for in-hospital mortality were older age, a higher sequential organ failure assessment (SOFA) score, sepsis, diabetes, hypertension, heart disease, and cancer.</p><p><strong>Conclusion: </strong>For AKI patients in ICUs, nephrology consultation reduced the risk of in-hospital mortality, particularly among those with multiple comorbidities. Therefore, nephrology consultation should not be omitted during ICU care.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"102-110"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41099956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of the living kidney donor profile index for predicting long-term posttransplant outcomes: results from the Korean Organ Transplantation Registry. 活体肾脏捐献者档案指数预测移植后长期结果的临床意义:来自韩国器官移植登记处的结果。
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2023-10-19 DOI: 10.23876/j.krcp.22.266
Jong Ho Kim, Sang Ho Lee, Jin Sug Kim, Hyeon Seok Hwang, Hyunmin Ko, Cheol-Woong Jung, Deok Gie Kim, Yeong Hoon Kim, Jaeseok Yang, Curie Ahn, Kyung Hwan Jeong

Background: The usefulness of the living kidney donor profile index (LKDPI) has not been widely demonstrated; therefore, it requires verification before clinical application. We analyzed the LKDPI using data from the Korean Organ Transplantation Registry (KOTRY) to confirm whether the LKDPI can be used to predict the survival of allografts in living donor kidney transplantation (LDKT) patients in Korea.

Methods: The study population was obtained from the KOTRY database. A total of 2,598 kidney recipients registered in the KOTRY database were enrolled between May 2014 and December 2020. Donor and recipient information was observed, and the LKDPI was measured.

Results: Median LKDPI score was 15.5 with a follow-up duration of 33.7 ± 16.1 months. According to LKDPI scores (group 1, <0; group 2, 0-20; group 3, 20-40; and group 4, >40), LKDPI group 4 had significantly higher death-censored graft loss than LKDPI group 1 (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.06- 3.40; p = 0.03). When divided based on the cutoff value (LKDPI, 36.6), the high LKDPI group had higher graft loss than the low LKDPI group (HR, 2.14; 95% CI, 1.37-3.34; p < 0.001). When follow-up was repeated after transplantation, it was confirmed that the higher the LKDPI value was, the lower the average estimated glomerular filtration rate (p < 0.001).

Conclusion: This study confirmed that LKDPI can serve as an independent predictor for assessing the risk of allograft failure and transplant outcomes in Korean LDKT patients.

背景:活体肾脏捐献者档案指数(LKDPI)的有用性尚未得到广泛证明;因此,它需要在临床应用前进行验证。我们使用韩国器官移植登记处(KOTRY)的数据分析了LKDPI,以确认LKDPI是否可以用于预测韩国活体供肾移植(LDKT)患者的同种异体移植物存活率。方法:从KOTRY数据库中获得研究人群。2014年5月至2020年12月期间,共有2598名肾脏接受者在KOTRY数据库中登记。观察供体和受体信息,并测量LKDPI。结果:LKDPI中位评分为15.5,随访时间为33.7±16.1个月。根据LKDPI评分(第1组,40),LKDPI第4组的死亡审查移植物损失显著高于LKDPI第一组(危险比[HR],1.89;95%置信区间[CI],1.06-3.40;p=0.03),高LKDPI组的移植物损失高于低LKDPI的组(HR,2.14;95%CI,1.37-3.34;p<0.001),平均估计肾小球滤过率越低(p<0.001)。结论:本研究证实LKDPI可以作为评估韩国LDKT患者同种异体移植失败风险和移植结果的独立预测指标。
{"title":"Clinical significance of the living kidney donor profile index for predicting long-term posttransplant outcomes: results from the Korean Organ Transplantation Registry.","authors":"Jong Ho Kim, Sang Ho Lee, Jin Sug Kim, Hyeon Seok Hwang, Hyunmin Ko, Cheol-Woong Jung, Deok Gie Kim, Yeong Hoon Kim, Jaeseok Yang, Curie Ahn, Kyung Hwan Jeong","doi":"10.23876/j.krcp.22.266","DOIUrl":"10.23876/j.krcp.22.266","url":null,"abstract":"<p><strong>Background: </strong>The usefulness of the living kidney donor profile index (LKDPI) has not been widely demonstrated; therefore, it requires verification before clinical application. We analyzed the LKDPI using data from the Korean Organ Transplantation Registry (KOTRY) to confirm whether the LKDPI can be used to predict the survival of allografts in living donor kidney transplantation (LDKT) patients in Korea.</p><p><strong>Methods: </strong>The study population was obtained from the KOTRY database. A total of 2,598 kidney recipients registered in the KOTRY database were enrolled between May 2014 and December 2020. Donor and recipient information was observed, and the LKDPI was measured.</p><p><strong>Results: </strong>Median LKDPI score was 15.5 with a follow-up duration of 33.7 ± 16.1 months. According to LKDPI scores (group 1, <0; group 2, 0-20; group 3, 20-40; and group 4, >40), LKDPI group 4 had significantly higher death-censored graft loss than LKDPI group 1 (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.06- 3.40; p = 0.03). When divided based on the cutoff value (LKDPI, 36.6), the high LKDPI group had higher graft loss than the low LKDPI group (HR, 2.14; 95% CI, 1.37-3.34; p < 0.001). When follow-up was repeated after transplantation, it was confirmed that the higher the LKDPI value was, the lower the average estimated glomerular filtration rate (p < 0.001).</p><p><strong>Conclusion: </strong>This study confirmed that LKDPI can serve as an independent predictor for assessing the risk of allograft failure and transplant outcomes in Korean LDKT patients.</p>","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"189-199"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54229817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The overlooked tool: kidney biopsy in progressive renal decline of type 2 diabetes patients. 您要对肾功能进行性减退的患者进行肾活检吗?
IF 2.9 3区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-01-01 Epub Date: 2024-12-11 DOI: 10.23876/j.krcp.24.999
Sang Youb Han
{"title":"The overlooked tool: kidney biopsy in progressive renal decline of type 2 diabetes patients.","authors":"Sang Youb Han","doi":"10.23876/j.krcp.24.999","DOIUrl":"10.23876/j.krcp.24.999","url":null,"abstract":"","PeriodicalId":17716,"journal":{"name":"Kidney Research and Clinical Practice","volume":" ","pages":"4-5"},"PeriodicalIF":2.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11838857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Kidney Research and Clinical Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1